In 2023, the Hong Kong Stock Exchange's 18A segment celebrated its fifth year of listing and the fifth set of standards for the Sci-Tech Innovation Board welcomed its fourth year. A total of 85 biotech companies have successfully gone public through this listing channel, driving the entire life sciences sector into high gear. After experiencing a boom and pursuit, as well as a cold winter and rationality, life sciences companies have never stopped innovating and breaking through. They continuously inject development momentum through technological innovation and bridge gaps through business model innovation. After experiencing dark moments, they still see themselves standing at a new starting point and forging ahead.
From September 27th to 28th, Frost & Sullivan (Frost & Sullivan, abbreviated as: F&S) will hold its second New Investment Expo and the 17th Frost & Sullivan Global Growth, Sci-Tech Innovation and Leadership Summit (abbreviated as "F&S New Investment Conference") at the Shangri-La Hotel in Pudong, Shanghai. The conference will grandly introducethe Life Sciences New Investment Summit Forumwith the theme of“New Directions for the Future & Forward Marching”bringing togetherindustry leaders, life sciences companies, investment institutions and professional service providersto focus on new investment and financing opportunities in life sciences, and jointly discuss the capital and industrial forces that enable companies to navigate cycles.
We sincerely invite you to attend this forum and embark on the successful journey of the capital market for life sciences companies!
Time:September 27th - 28th, 2023
Venue:Shangri-La Hotel in Pudong, Shanghai
Sponsors:Frost & Sullivan, China Biomedical Industry Chain Innovation and Transformation Alliance (CBIITA)
About Zephyrm Biotechnologies
Beijing Zephyrm Biotechnologies Co., Ltd. (Zephyrm Biotechnologies) was established in 2018 and is a biopharmaceutical company focusing on stem cell drug research, development and production. It was recognized as a national high-tech enterprise in 2021 and a "specialized, refined, characteristic and innovative" small and medium-sized enterprise in Beijing in 2022. We firmly believe that stem cell drugs will bring revolutionary breakthroughs to humanity in defeating diseases, benefiting human health and promoting social progress. Therefore, the company adheres to the belief of "a promise for the future, a trust in life, leading the industry, contributing to society", and develops and produces high-quality stem cell drugs with a scientific and rigorous attitude, constantly striving for progress, promoting innovation and achievement transformation of stem cell technology, and aiming to become a conscientious, warm-hearted and respected enterprise.
Introduction to Speakers
Dr. Jia Yi is an expert in drug clinical development and a surgeon, graduated from Imperial College London and Peking Union Medical College. He has worked at Bayer and HuiLing, and served as the China clinical R&D head of Allergan.
01
Consultation on Participation
Registration Consultation | Business Cooperation | Media Cooperation
Contact Person:
Ms. Li 18917935734 (WeChat ID)
Ms. Bai 18019047843 (WeChat ID)
02
Highlights from the Previous Session
